Turcotte et al., 2001
While patients are showing some willingness to absorb cost hikes associated with reduced payer coverage for GLP-1 drugs, theyre far from the only stakeholders to be impacted by shifting policies: Biopharma Pharmaceutical developers could face slower market growth, particularly for newer indications like cardiovascular risk reduction and addiction treatment
Joshua Starbuck , MDchief medical officer, Makena Health (Maui), a concierge longevity clinic (Im using quotes because the phrase itself is hyperbole) that markets peptides
What if we want to stop the medication later
Instead of introducing something completely foreign, it mimics a hormone your body already uses
Lilly and Novo, the manufacturers of Wegovy and Zepbound, had agreed to sell these medications to plans for $245 per month, and plans had to agree to monthly copayments of $50 or less